Immatics (IMTX) Non-Current Deffered Revenue (2019 - 2026)
Immatics (IMTX) posted Non-Current Deffered Revenue of $21.6 million for Q4 2025, down 30.82% sequentially from $31.2 million in Q2 2025, and down 40.88% YoY from $36.5 million in Q4 2024.
Analysis
Immatics (IMTX) Non-Current Deffered Revenue (2019 - 2026) Analysis & Trends
Immatics has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $21.6 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 40.88% year-over-year to $21.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.6 million (down 40.88% YoY) and the FY2025 annual result came in at $20.9 million, down 43.34% from the prior year.
- Non-Current Deffered Revenue declined to $21.6 million in Q4 2025 per IMTX's latest filing, from $31.2 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $124.3 million in Q4 2023 and troughed at $21.6 million in Q4 2025.
- A 5-year average of $68.3 million and a median of $66.6 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2022 and 2024: Non-Current Deffered Revenue surged 64.28% in 2022, then plunged 70.63% in 2024.
- Over 5 years, Non-Current Deffered Revenue stood at $55.2 million in 2021, then soared by 40.1% to $77.3 million in 2022, then surged by 60.82% to $124.3 million in 2023, then sank by 70.63% to $36.5 million in 2024, then plunged by 40.88% to $21.6 million in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $21.6 million, $31.2 million, and $36.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | 15.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.85 Mn |
| Mar 31, 2026 | 18.59 Mn |
| Dec 31, 2025 | 21.58 Mn |
| Sep 30, 2025 | 26.24 Mn |
| Jun 30, 2025 | 31.20 Mn |
| Mar 31, 2025 | 30.68 Mn |
| Dec 31, 2024 | 36.50 Mn |
| Sep 30, 2024 | 57.76 Mn |
| Jun 30, 2024 | 81.09 Mn |
| Mar 31, 2024 | 99.25 Mn |
| Dec 31, 2023 | 124.30 Mn |
| Sep 30, 2023 | 59.72 Mn |
| Jun 30, 2023 | 58.32 Mn |
| Mar 31, 2023 | 70.07 Mn |
| Dec 31, 2022 | 77.29 Mn |
| Sep 30, 2022 | 104.07 Mn |
| Jun 30, 2022 | 123.05 Mn |
| Mar 31, 2022 | 76.08 Mn |
| Dec 31, 2021 | 55.17 Mn |
| Sep 30, 2021 | 61.60 Mn |